Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Haley, Connie A. ; Macias, Patricia ; Jasuja, Supriya ; Jones, Betsy A. ; Rowlinson, Marie-Claire ; Jaimon, Roshni ; Onderko, Pennelyn ; Darnall, Elaine ; Gomez, Maria E. ; Peloquin, Charles ; Ashkin, David ; Goswami, Neela D.
• Description:
  The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.
• Subjects:
  Antitubercular Agents Diarylquinolines Humans Linezolid Tuberculosis Tuberculosis, Multidrug-Resistant
• Source:
  Emerg Infect Dis. 27(1):332-334
• Pubmed ID:
  33227229
• Pubmed Central ID:
  PMC7774582
• Document Type:
  Journal Article
• Place as Subject:
  South Africa ; United States
• Location:
  Africa ; North America
• Volume:
  27
• Issue:
  1
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:626836f2d662b3c90eb24bff03b21db20069426e84c1f5db36da5b16735559c9
• Download URL:
  https://stacks.cdc.gov/view/cdc/100004/cdc_100004_DS1.pdf
• File Type:
  [PDF - 616.11 KB ]